imSAVAR Stakeholder Survey: Views on Adverse Outcome Pathways & Model Grading Systems
The imSAVAR consortium selected four modes of action (MoAs)—CAR Ts, CPIs, BiTEs and IL-2 TREGs—needing …
The imSAVAR consortium selected four modes of action (MoAs)—CAR Ts, CPIs, BiTEs and IL-2 TREGs—needing …
The advances in cancer immunotherapy come with several roadblocks limiting their widespread use and their …
The third and last of the series of planned imSAVAR Stakeholder Workshops took place over …
The imSAVAR second stakeholder workshop was held on the fourth of November 2020. There were …
One of the objectives of imSAVAR is to build a stakeholder community and also get …